Cloud-clone
SKU:MAB215Hu21
Monoclonal Antibody to Fibrinogen Beta Chain (FGB)
Monoclonal Antibody to Fibrinogen Beta Chain (FGB)
Couldn't load pickup availability
Western blotting: 0.5-2µg/mL;1:500-2000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
Product No.
MAB215Hu21
Organism Species
Homo sapiens (Human).
Source
Monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
C1
Ig Isotype
IgG2b Kappa
Purification
Protein A + Protein G affinity chromatography
Label
None
Immunogen
RPB215Hu02-Recombinant Fibrinogen Beta Chain (FGB)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
1mg/ml
Organism Species More
n/a
Applications
WB,IHC
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against FGB. It has been selected for its ability to recognize FGB in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-3µg/mL
Immunohistochemistry: 5-30µg/mL
Immunocytochemistry: 5-30µg/mL
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html |
| Microbial Pathogenesis | Crystal structure of GAPDH of Streptococcus agalactiae and characterization of its interaction with extracellular matrix molecules Pubmed: 30553015 |
| GLYCOCONJUGATE JOURNAL | Nattokinase-heparin exhibits beneficial efficacy and safety—an optimal strategy for CKD patients on hemodialysis Pubmed: 30788657 |
Share
